ARCHIVES

DCT Board Approves More Than $25 Million In Contract Recompetitions, Two New Contracts

This article is from The Cancer Letter archive.

Vol. 16 No. 08 | February 23, 1990

Download PDF Visit The Full Archive

Related Articles

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

April 5, 1985

EntreMed Issued U.S. Patent For Active Parts Of Endostatin.

March 2, 2001

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

July 31, 2009

Trials Approved In October

December 28, 2001

DCCR Cancer Information Systems Program Renewed For Three More Years; Two Dropped, Two Added

September 1, 1978

CMS Looks At Coverage of Two Agents Approved on Surrogate Endpoints

February 21, 2003